A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 19 sites in 7 countries. Open to participants aged 12 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 20th largest by enrollment, is the only one that started in 2023, is one of 19 in phase 3, and was the 20th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Months to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2023.
This study's enrollment of 67 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 65th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2023, is one of 62 in phase 3, and was the 114th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The study evaluates the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF participants 2 to less than (\<) 24 months of age.
Key Inclusion Criteria:
Participants who have at least 1 F508del mutation in the CF transmembrane conductance regulator (CFTR) gene or another ELX/TEZ/IVA-responsive CFTR mutation
Key Exclusion Criteria:
History of any illness or any clinical condition that, in the opinion of the investigator, might either confound the results of the study or pose an additional risk in administering study drug(s) to the participant
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants received ELX 40 milligram (mg)/ TEZ 20 mg/IVA 30 mg fixed-dose combination (FDC) granules once every morning (qAM) and 25 mg IVA once every evening (qPM) for 15 Days.
Drug: ELX/TEZ/IVA · Drug: IVA
Participants received one of three dosing regimens based on their body weight at Day 1 . Dosage 1: ELX 80 mg qAM/TEZ 40 mg qAM /IVA 60 mg qAM FDC granules and 59.5 IVA mg qPM; Dosage 2: ELX 60 mg qAM /TEZ 30 mg qAM /IVA 45 mg qAM FDC granules and 50 mg IVA qPM; Dosage 3: ELX 40 mg qAM / TEZ 20 mg qAM /IVA 30 mg qAM FDC granules and 25mg IVA qPM. Part B included some participants from Part A and newly enrolled participants.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination granules for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Granules for oral administration
Also known as: VX-770, ivacaftor
Part A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)
Time frame: At Day 15
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 43
Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 28
Part B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEZ, M1-IVA)
Time frame: Day 15, Week 4, 12 and 16
Part B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24
Time frame: From Baseline through Week 24
The study comprised of two parts: Part A and Part B. Part A enrolled and dosed 15 participants. Part B enrolled 55 participants, of whom 54 received at least one dose of study drug. Three participants who completed Part A subsequently continued into Part B and are therefore included in both study parts. As a result, the total number of unique participants enrolled across Parts A and B was 67.
| Milestone | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Started | 15 | 0 |
| Safety set | 15 | 0 |
| Completed | 15 | 0 |
| Not completed | 0 | 0 |
| Milestone | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Started | 0 | 55 |
| Safety set | 0 | 54 |
| Completed | 0 | 53 |
| Not completed | 0 | 2 |
| Withdrew: Prematurely discontinued study | 0 | 1 |
| Withdrew: Never dosed | 0 | 1 |
| microgram per milliliter (μg/mL) | Part A: ELX/TEZ/IVA |
|---|---|
| ELX | 0.907 ± 0.447 |
| TEZ | 0.691 ± 0.245 |
| IVA | 0.151 ± 0.0669 |
| M23-ELX | 0.474 ± 0.159 |
| M1-TEZ | 4.56 ± 1.46 |
| M1-IVA | 0.458 ± 0.178 |
| Participants | Part A: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 14 |
| Participants with SAEs | 0 |
| Participants | Part B: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 53 |
| Participants with SAEs | 6 |
| microgram per milliliter (μg/mL) | Part B: ELX/TEZ/IVA |
|---|---|
| Dosage1: ELX(Day 15) | 2.74 ± 1.87 |
| Dosage1: ELX(Week 4) | 2.36 ± 1.10 |
| Dosage1: ELX(Week 12) | 2.27 ± 1.47 |
| Dosage1: ELX(Week 16) | 2.45 ± 1.34 |
| Dosage1: TEZ (Day 15) | 1.74 ± 0.894 |
| Dosage1: TEZ(Week 4) | 1.75 ± 1.02 |
| Dosage1:TEZ(Week 12) | 1.71 ± 1.13 |
| Dosage1: TEZ (Week 16) | 1.61 ± 0.729 |
| Dosage1: IVA(Day 15) | 0.400 ± 0.244 |
| Dosage1: IVA (Week 4) | 0.432 ± 0.317 |
| Dosage1: IVA(Week 12) | 0.407 ± 0.376 |
| Dosage1: IVA (Week 16) | 0.451 ± 0.298 |
| Dosage1: M23-ELX(Day 15) | 2.03 ± 1.37 |
| Dosage1: M23-ELX(Week 4) | 1.74 ± 0.896 |
| Dosage1: M23-ELX(Week 12) | 1.77 ± 1.15 |
| Dosage1: M23-ELX(Week 16) | 1.82 ± 1.02 |
| Dosage1: M1-TEZ(Day 15) | 7.28 ± 2.22 |
| Dosage1: M1-TEZ(Week 4) | 7.68 ± 2.56 |
| Dosage1: M1-TEZ(Week 12) | 7.62 ± 2.08 |
| Dosage1: M1-TEZ(Week 16) | 7.44 ± 1.91 |
| Dosage1: M1-IVA(Day 15) | 1.07 ± 0.564 |
| Dosage1: M1-IVA (Week 4) | 1.18 ± 0.596 |
| Dosage1: M1-IVA(Week 12) | 1.25 ± 0.817 |
| Dosage1: M1-IVA(Week 16) | 1.28 ± 0.694 |
| Dosage2: ELX (Day 15) | 1.92 ± 1.42 |
| Dosage2: ELX (Week 4) | 2.49 ± 1.83 |
| Dosage2: ELX (Week 12) | 3.05 ± 2.30 |
| Dosage2: ELX (Week 16) | 2.45 ± 1.00 |
| Dosage2: TEZ (Day 15) | 1.57 ± 1.20 |
| Dosage2: TEZ (Week 4) | 1.54 ± 0.725 |
| Dosage2: TEZ (Week 12) | 1.54 ± 0.858 |
| Dosage2: TEZ (Week 16) | 1.52 ± 0.547 |
| Dosage2: IVA (Day 15) | 0.435 ± 0.434 |
| Dosage2: IVA (Week 4) | 0.468 ± 0.489 |
| Dosage2: IVA (Week 12) | 0.571 ± 0.695 |
| Dosage2: IVA (Week 16) | 0.547 ± 0.358 |
| Dosage2: M23-ELX (Day 15) | 1.26 ± 0.854 |
| Dosage2: M23-ELX (Week 4) | 1.89 ± 1.35 |
| Dosage2: M23-ELX (Week 12) | 2.16 ± 1.75 |
| Dosage2: M23-ELX (Week 16) | 1.66 ± 0.819 |
| Dosage2: M1-TEZ (Day 15) | 6.81 ± 2.53 |
| Dosage2: M1-TEZ (Week 4) | 7.75 ± 2.09 |
| Dosage2: M1-TEZ (Week 12) | 6.66 ± 2.35 |
| Dosage2: M1-TEZ (Week 16) | 7.58 ± 1.38 |
| Dosage2: M1-IVA (Day 15) | 1.09 ± 0.956 |
| Dosage2: M1-IVA (Week 4) | 1.37 ± 1.33 |
| Dosage2: M1-IVA (Week 12) | 1.36 ± 0.970 |
| Dosage2: M1-IVA (Week 16) | 1.64 ± 1.04 |
| Millimole per liter (mmol/L) | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24 | -71.8 (-75.4 to -68.2) |
Collected over From Day 1 Through Safety Follow-up Period (up to Day 43 for Part A and up to Week 28 for Part B). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: ELX/TEZ/IVA | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Part B: ELX/TEZ/IVA | 0/54 (0%) | 6/54 (11.1%) | 53/54 (98.1%) |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/15 | 4/54 |
| Respiratory syncytial virus infectionInfections and infestations | 0/15 | 1/54 |
| Viral upper respiratory tract infectionInfections and infestations | 0/15 | 1/54 |
| Pseudomonas test positiveInvestigations | 0/15 | 1/54 |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 3/15 | 28/54 |
| PyrexiaGeneral disorders | 1/15 | 21/54 |
| Upper respiratory tract infectionInfections and infestations | 5/15 | 15/54 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/15 | 15/54 |
| ConstipationGastrointestinal disorders | 4/15 | 7/54 |
| DiarrhoeaGastrointestinal disorders | 4/15 | 8/54 |
| NasopharyngitisInfections and infestations | 0/15 | 14/54 |
| VomitingGastrointestinal disorders | 1/15 | 13/54 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/15 | 12/54 |
| RhinitisInfections and infestations | 2/15 | 12/54 |
All participants who are enrolled (defined as participants having data in the clinical database) and carry the intended CFTR allele mutation and received at least 1 dose of study drug were included in the baseline analysis.
| Age, Categorical(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — <=18 years | 15 |
| Part A (15 Days) — Between 18 and 65 years | 0 |
| Part A (15 Days) — >=65 years | 0 |
| Part B (24 Weeks) — <=18 years | 54 |
| Part B (24 Weeks) — Between 18 and 65 years | 0 |
| Part B (24 Weeks) — >=65 years | 0 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — Female | 4 |
| Part A (15 Days) — Male | 11 |
| Part B (24 Weeks) — Female | 22 |
| Part B (24 Weeks) — Male | 32 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — Hispanic or Latino | 0 |
| Part A (15 Days) — Not Hispanic or Latino | 15 |
| Part A (15 Days) — Not Collected per Local Regulations | 0 |
| Part B (24 Weeks) — Hispanic or Latino | 1 |
| Part B (24 Weeks) — Not Hispanic or Latino | 50 |
| Part B (24 Weeks) — Not Collected per Local Regulations | 3 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — White | 14 |
| Part A (15 Days) — Asian | 0 |
| Part A (15 Days) — Other | 1 |
| Part A (15 Days) — Not collected per local regulations | 0 |
| Part B (24 Weeks) — White | 51 |
| Part B (24 Weeks) — Asian | 2 |
| Part B (24 Weeks) — Other | 1 |
| Part B (24 Weeks) — Not collected per local regulations | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Jun 2023 to primary completion in Sep 2025, 26 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 26 months is close to that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →